Metabolic profiling of bile in cholangiocarcinoma using in vitro magnetic resonance spectroscopy  by Sharif, Amar W. et al.
ORIGINAL ARTICLE
Metabolic profiling of bile in cholangiocarcinoma using in vitro
magnetic resonance spectroscopy
Amar W. Sharif1, Horace R. T. Williams1, Temi Lampejo1, Shahid A. Khan1, Devinder S. Bansi1, David Westaby1,
Andrew V. Thillainayagam1, Howard C. Thomas1, I. Jane Cox2 & Simon D. Taylor-Robinson1
1Hepatology and Gastroenterology Section, Department of Medicine and 2Imaging Sciences Department, MRC Clinical Sciences Centre, Faculty of
Medicine, Imperial College London, London, UK
Abstracthpb_185 396..402
Objectives: Cholangiocarcinoma (CCA) has a poor prognosis and its aetiology is inadequately under-
stood. Magnetic resonance spectroscopy (MRS) of bile may provide insights into the pathogenesis of
CCA and help identify novel diagnostic biomarkers. The aim of this study was to compare the chemical
composition of bile from patients with CCA with that of bile from patients with benign biliary disease.
Methods: Magnetic resonance spectra were acquired from the bile of five CCA patients and compared
with MRS of control bile from patients with benign biliary disease (seven with gallstones, eight with
sphincter of Oddi dysfunction [SOD], five with primary sclerosing cholangitis [PSC]). Metabolic profiles
were compared using both univariate and multivariate pattern-recognition analysis.
Results: Univariate analysis showed that levels of glycine-conjugated bile acids were significantly
increased in patients with CCA, compared with the benign disease groups (P = 0.002). 7b primary bile
acids were significantly increased (P = 0.030) and biliary phosphatidylcholine (PtC) levels were reduced
(P = 0.010) in bile from patients with CCA compared with bile from gallstone patients. These compounds
were also of primary importance in the multivariate analysis: the cohorts were differentiated by partial
least squares discriminant analysis (PLS-DA).
Conclusions: These preliminary data suggest that altered bile acid and PtC metabolism play an
important role in CCA aetiopathogenesis and that specific metabolites may have potential as future
biomarkers.
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Introduction
Cholangiocarcinoma (CCA) is the leading cause of
death from a primary liver tumour in many developed coun-
tries.1,2 Although a relatively rare cancer, the incidence and mor-
tality of CCA have been increasing on a global scale for reasons
which remain to be determined.1–3 Cholangiocarcinoma has a
high mortality and poor prognosis, with a 5-year survival of
<5%, as a result of its late clinical presentation. Consequently,
most tumours are at an advanced stage at the time of
diagnosis.3
Confirmation of CCA diagnosis is often difficult and is cur-
rently based on a high index of clinical suspicion, depending on
serum levels of the cancer antigen tumour marker, carbohydrate
antigen (CA) 19-9, and hepatobiliary imaging, with additional
histological or cytological verification if tumour tissue or bile can
be reliably obtained. Although in widespread use, serum CA19-9
has a poor sensitivity (50–60%) for the diagnosis of CCA.4,5 Cyto-
logical examination of bile also has a poor detection rate for
malignant biliary disease.6 Despite improvements in biliary cyto-
logical examination using digital image analysis (DIA) and fluo-
rescent in situ hybridization (FISH), the ability to distinguish
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benign from malignant ductular epithelium remains sub-
optimal.7 Tissue biopsies often yield negative findings as a result
of marked fibrosis and because no pathognomonic immunohis-
tochemistry exists.
In order to improve diagnosis and prognosis, there is a pressing
need to identify biological markers for early disease detection, as
well as to enhance the understanding of disease aetiopathogenesis.
Sampling of bile for diagnostic purposes has become common
clinical practice since the introduction of endoscopic retrograde
cholangiopancreatography (ERCP). Exposure of the biliary epi-
thelium to bile and its constituents make bile an ideal biofluid for
analytical profiling studies in malignancy of the biliary tract. The
analysis of the metabolic profile of bile may therefore provide
insights into the pathogenesis of CCA, as well as identifying bio-
chemical disease markers.
Magnetic resonance spectroscopy (MRS) is a non-invasive and
sensitive analytical technique which can determine both
chemical composition and molecular structural information
from non-homogeneous biological samples without a priori
knowledge. Specific metabolites of interest may be quantified
and analysed using conventional univariate statistical methods;
the data may also be analysed using a multivariate,
pattern-recognition approach with techniques such as principal
components analysis (PCA) and partial least squares discrimi-
nant analysis (PLS-DA). This has been termed a ‘metabonomic’
or ‘metabolomic’ approach.8 In vitro MRS studies on bile
have provided information on composition, structure and
function, as well as on the metabolism and biliary excretion of
xenobiotics.9–11 A major advantage of the technique is that
the sample can be studied intact, which allows for
subsequent study as required. Recently, MRS studies on bile in
patients with pancreatic carcinoma observed an alteration
in bile composition and also identified a potential cancer
biomarker.12
However, bile collected at ERCP is frequently contaminated by
the contrast agent used; two previously published studies investi-
gating the metabolic composition of bile from CCA patients using
MRS were flawed by such contamination, which resulted in domi-
nating spectral resonances that may confound the measurement
of metabolites.11,13 A secondary major drawback of these studies is
that bile samples were analysed from patients with marked
cholestasis, which could partially account for the spectral differ-
ences observed.
In this study, uncontaminated bile was analysed from non-
cholestatic patients. Our aims were to assess and quantify differ-
ences in the chemical composition of bile from patients with
cancer of the biliary tree, compared with bile from patients with
benign biliary disease, using in vitro proton (1H) MRS. The pre-
dominant lipid metabolites, bile acids and phosphatidylcholine
(PtC), were selected for specific study, owing to their proposed
role in cholangiocarcinogenesis.11,14,15 A further aim was to iden-
tify potential disease markers in bile in order to improve the
diagnosis and prognosis of CCA.
Materials and methods
This study was approved by the Research Ethics Committee of
Hammersmith Hospital, London (HHREC no. AM1073/0086).
The study conformed to the ethical guidelines outlined in the
1975 Declaration of Helsinki. Written, informed consent was
obtained from all patients. Four millilitres of contrast-free bile
were obtained at ERCP, after an overnight fast, from 25 patients
with malignant and benign conditions of the biliary tree.
MR sample preparation
Bile samples, stored at –80 °C and protected from light, were
thawed to room temperature and pH was measured; 600 ml of bile
were then transferred to a 5-mm glass nuclear magnetic resonance
(NMR) tube. A sealed 4-mm stem coaxial NMR insert, containing
50 ml of an internal reference standard solution (35 ml of sodium
trimethylsilyl-[2H4] propionate [TSP] 1 mg/ml dissolved in deu-
terium oxide), was placed inside the NMR tube.
MR data acquisition
In vitro 1H MRS was performed using an ECP+ 500-Mhz NMR
spectroscopy system (JEOL Instruments, Tokyo, Japan) and an
11.7-Tesla superconducting magnet. The 1H MR spectra were
obtained using a pulse-collect sequence (90-degree pulse angle,
acquisition duration 4.4 s, relaxation delay 20 s, 32 data collects),
in combination with a water presaturation technique to reduce
the dominant water signal. Magnetic resonance spectra were also
acquired using the Hahn spin-echo (relaxation delay 2 s, time to
echo 135 ms, 64 data collects) to aid metabolite peak assignments
caused by the phase inversion of some of the coupled signals.
Spectral interpretation and analysis
The data were processed using the KnowItAll Informatics System
Version 7.9 (Bio-Rad Laboratories, Philadelphia, PA, USA). Free
induction decays were zero-filled, and multiplied by an exponen-
tial line-broadening function of 0.8 Hz and then subjected to
Fourier transformation. The MR spectra were manually phased
and a baseline correction was applied. Peaks were assigned on the
basis of published literature relative to TSP (d = 0.00 ppm).16 The
cluster of peaks d 0.70–1.10 ppm was assigned as one region with
contributions from H-19 bile acid proton, H-21 bile acid proton
and cholesterol. The peaks d 3.09 ppm and d 3.57 ppm were
assigned to the taurine moiety in taurine-conjugated bile acids.
The peak d 3.71 ppm was assigned to the glycine moiety of
glycine-conjugated bile acids. The peaks d 3.24 ppm and
d 1.29 ppm were the most prominent resonances attributable to
PtC, and assigned to the choline head group and (CH2)n chain,
respectively.
For relative quantification, peak areas were manually integrated
and expressed in arbitrary units (u), as a percentage ratio to the
total spectral signal (range d 10.00–0.20 ppm). The residual water
signal (range d 5.20–4.50 ppm) was excluded from the analysis.
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Univariate statistical analysis was carried out using spss for
Windows, Version 14.0 (SPSS, Inc., Chicago, IL, USA). The non-
parametric Kruskal–Wallis test was used for comparisons of
metabolite concentrations between the different disease groups.
The Mann-Whitney U-test was used for comparisons between
two independent disease groups.
Multivariate pattern-recognition analysis
Using an ‘intelligent bucketing’ algorithm in KnowitAll Version
7.9, each spectrum was divided into smaller regions (bins), of 0.04
 0.02 ppm, ensuring no overlap across binned regions. These
regions were integrated and normalized to the total spectral signal
and the data were mean-centred before multivariate analysis.
Principal component multivariate analysis
Principal component analysis is an ‘unsupervised’ technique in
that it does not rely on a priori knowledge of the cohort to which
samples belong. It facilitates the visualization of a multivariate
dataset through data reduction, to identify and visualize inherent
patterns of variance within the dataset. The first principal com-
ponent is essentially a linear combination of the original variables,
explaining the maximum amount of variance in the dataset; the
second principal component describes the second greatest, and so
on. Each sample is represented in the PCA scores plot generated;
inspection of the corresponding loadings plot allows visualization
of the metabolites responsible for the variation seen in the scores
plot.
Partial least squares discriminant analysis
Data were then analysed by PLS-DA using Pirouette Version 4.0
(Infometrix, Inc., Woodinville, WA, USA). This linear regression
technique relates the NMR spectroscopic variables, corresponding
to metabolites, to the class membership of the sample, allowing
the identification and visualization of metabolites responsible for
differences between classes. It is thus ‘supervised’. The data filter-
ing technique of orthogonal signal correction (OSC) was used to
remove variation in the spectra not directly related to the physi-
ological condition being studied, and to minimize the possible
influence of inter-individual variation.17,18 The discriminatory
power of each model was validated using a cross-validation
technique whereby each sample in turn was excluded from the
analysis, a model was created from the other samples and the class
membership of the excluded sample was predicted (‘leave-one-
out’ cross-validation).19,20
Results
Patient demographics
Five inoperable CCA patients (four male, one female; mean age 73
years, range 58–82 years) were recruited. Three had hilar bismuth
grade 3 tumours and bile was collected downstream of the lesion.
Two had distal tumours and bile was collected upstream. Of the
five CCA patients, only two had an elevated CA19-9 (240 U/ml
and 26 954 U/ml, respectively). Histological diagnosis was con-
firmed in two patients. Diagnosis in the other three patients was
based on clinical presentation and imaging findings. Twenty
patients with non-malignant biliary disease (seven with choledo-
cholithiasis [gallstones], eight with sphincter of Oddi dysfunction
[SOD] and five with primary sclerosing cholangitis [PSC] with
biliary strictures) were included in the study. Importantly, bile
samples were stratified according to ambient serum bilirubin
levels. The mean serum bilirubin level for all the bile samples
analysed was 16.2 mmol/l (standard deviation 13.2 mmol/l).
The normal reference range was 3–17 mmol/l. The clinico-
pathological details of patients are summarized in Table 1. The age
and gender of the cohort were not normally distributed. The four
groups were therefore analysed separately and in combination.
Proton NMR spectroscopy of bile samples
The human bile 1H MR spectrum is dominated by broad reso-
nances arising from bile acids, phospholipids and cholesterol. A
representative 1H MR spectrum of bile from a patient with CCA is
shown in Fig. 1. The region of interest d 3.00–4.00 ppm has been
expanded to illustrate the assignment to resonances arising from
taurine- and glycine-conjugated bile acids (Fig. 2).
Univariate analysis
Biliary levels of glycine-conjugated bile acids (d 3.71 ppm, rela-
tive to the total spectral integral) were significantly higher in
patients with CCA than in the benign biliary disease groups (P =
0.002, Kruskal–Wallis test). The level of these glycine-conjugated
Table 1 Clinico-pathological details of patients and bile samples (mean and range). Kruskal–Wallis tests showed significant differences
between the four disease groups according to age (P = 0.011) and gender (P < 0.001)
CCA Gallstones SOD PSC
Age, years 73 (58–82) 64 (45–79) 47 (27–62) 45 (28–66)
Sex, M : F 4 : 1 0 : 7 0 : 8 5 : 0
Bilirubin, mmol/l 16 (8–31) 22 (5–57) 10 (2–33) 19 (8–42)
ALP, IU/l 637 (69–2423) 222 (76–426) 96 (50–130) 242 (63–325)
pH of bile 7.80 (7.26–8.40) 7.80 (7.50–8.10) 7.78 (6.8–8.45) 8.02 (7.50–8.70)
CCA, cholangiocarcinoma; SOD, sphincter of Oddi dysfunction; PSC, primary sclerosing cholangitis; M, male; F, female; ALP, alkaline phosphatase
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bile acids was higher in the CCA group than in patients with
SOD and PSC, at a median of 1.00 u (interquartile range [IQR]
0.78–1.59 u) vs. 0.70 u (IQR 0.47–0.85 u) (P = 0.030) and 0.56 u
(IQR 0.44–0.74 u) (P = 0.056), respectively. By contrast, there
was no difference in the levels of taurine-conjugated bile
acids (d 3.57 ppm) across the patient groups (P = 0.12, Kruskal–
Wallis test). However, the relative ratio of glycine- to taurine-
conjugated bile acids was greater in the CCA group, at 1.11, than
in the other patient groups, in which it was reduced to 0.82 in
the SOD group, 0.64 in the PSC group and 0.97 in the gallstones
group. Median levels of the 7b primary bile acids (cholic acid
and chenodeoxycholic acid, d 3.45 ppm) were significantly
elevated in the bile of patients with CCA vs. that of patients with
gallstones: median 0.76 u (IQR 0.56–1.32 u) vs. 0.44 u (IQR
0.09–0.71 u) (P = 0.030). Levels of the peaks assigned to the
choline moiety of the PtC head group d 3.24 ppm and the
(CH2)n tail group d 1.29 ppm were significantly lower in bile
from patients with CCA compared with bile from the gallstone
control group, at a median of 4.03 u (IQR 3.94–4.66 u) vs. 4.61 u
(IQR 4.32–6.09 u) (P = 0.018) and a median of 24.99 u (IQR
22.68–27.06 u) vs. 29.08 u (IQR 25.10–34.61 u) (P = 0.010),
respectively.
Multivariate pattern-recognition analysis
Principal component analysis of all samples revealed no signifi-
cant outliers. The analyses demonstrated the most notable clus-
tering when CCA samples were compared with SOD samples
(Fig. 3). Models were then constructed using OSC-PLS-DA to
investigate the ability of this technique to distinguish between the
cohorts studied. Using this method, with ‘leave-one-out’ cross-
validation, the CCA samples were discriminated from all 20 non-
malignant samples with a sensitivity of 80%, specificity of 95%,
positive predictive value of 80% and negative predictive value of
95% (Table 2) (one CCA sample and one non-cancer patient were
incorrectly predicted). The major metabolites contributing to this
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separation were PtC, H-18 bile acids (resonance d 0.70 ppm) and
taurine-conjugated bile acids.
Other OSC-PLS-DA models were also constructed, comparing
CCA with each of the control groups: the excellent discrimination
achieved is demonstrated in Table 2, which shows the predictive
abilities of the models constructed. The major discriminatory
metabolites for these models were: glycine- and taurine-
conjugated bile acids (CCA vs. PSC); PtC and taurine-conjugated
bile acids (CCA vs. gallstones), and PtC (CCA vs. SOD).
Discussion
In this MR study, 25 contrast-free, non-cholestatic bile samples
were analysed and compared using 1H MRS. Previous studies have
been hampered by the contamination of samples with contrast
agent, and by the marked cholestastic nature of the bile samples
studied.11,13 Despite a small and heterogeneous sample popula-
tion, our data demonstrated important differences in the biliary
metabolic profile in comparisons between malignant and benign
biliary disease. The patient study groups could be clearly distin-
guished using OSC-PLS-DA. The major findings of this study
were significant differences in the levels of primary bile acids, their
glycine conjugates and PtC in bile from patients with CCA com-
pared with bile from non-malignant control groups. When analy-
sed using univariate statistical methods, normalized signal levels
of glycine-conjugated bile acids were significantly higher in CCA
bile, compared with controls; these metabolic differences contrib-
uted strongly to the PLS-DA models and thus corroborated the
findings. The greatest difference was seen when comparing CCA
bile with SOD bile. It is also worth noting that the ratio of glycine-
to taurine-conjugated bile acids was greater in the CCA bile com-
pared with control bile. The ratio of conjugated to unconjugated
bile acids, and the ratio of glycine to taurine bile acid conjugates,
vary in specific hepatobiliary diseases and cholestasis,21,22 although
until now there have been no published reports quantifying bile
acid conjugates in bile from patients with CCA.
In vitro studies have shown that bile acids play a role in CCA
aetiopathogenesis and, furthermore, bile acid abnormalities and
toxicity have been implicated in other biliary diseases, such as
primary biliary cirrhosis and PSC, in addition to colorectal
carcinoma.23–25 The in vitro MR data presented in this study
suggest that primary bile acids and their glycine conjugates may be
elevated in CCA bile in the absence of clinical cholestasis and
therefore these agents are potential disease biomarkers, requiring
further evaluation in larger-scale studies.
Multivariate analysis highlighted PtC as the major metabolite in
bile distinguishing the CCA group from the disease control
groups. Levels of PtC were significantly lower in CCA bile com-
pared with bile from patients with gallstones. We have previously
shown differences in phospholipid metabolites that may help to
distinguish between malignant and non-malignant causes of pan-
creaticobiliary obstruction; a reduced PtC resonance was seen in
bile from the majority of patients with hepatobiliary cancer com-
pared with bile from patients with non-malignant indications for
ERCP.11 This finding has also more recently been confirmed by
Albiin and co-workers in a comparison of bile from patients with
CCA with bile from patients with PSC.13 An in vivo NMR study of
bile after biliary decompression suggested that the altered metabo-
lism of phosphorus-containing metabolites may be a useful
Figure 3 Principal component analysis demonstrated the most
notable clustering when cholangiocarcinoma (CCA) samples were
compared with sphincter of Oddi dysfunction (SOD) samples
Table 2 Predictive abilities of the orthogonal signal correction partial least squares discriminant analysis (OSC-PLS-DA) models constructed
CCA vs. all non-malignant CCA vs. SOD CCA vs. PSC CCA vs. GS
Sensitivity 80% 80% 100% 100%
Specificity 95% 100% 100% 86%
PPV 80% 100% 100% 83%
NPV 95% 89% 100% 100%
CCA, cholangiocarcinoma; SOD, sphincter of Oddi dysfunction; PSC, primary sclerosing cholangitis; GS, gallstones; PPV, positive predictive value;
NPV, negative predictive value
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indicator of malignancy in jaundiced patients with hepatobiliary
disease.26 Phosphatidylcholine, a cytoprotective and dominant
biliary phospholipid, is synthesized in the hepatocyte and trans-
ported into the biliary canaliculus by the flippase multidrug resis-
tant protein 3 (MDR3).27 Animal studies have shown that MDR2
knockout mice (mdr 2-/-) develop CCA after prolonged bile acid
exposure.28 In humans, genetic mutations in the ABCB4 gene
(which encodes the protein MDR3) lead to reduced or absent
phospholipid export into the bile, thus exposing the biliary epi-
thelium to ‘toxic’ bile, and it has been postulated that these indi-
viduals may be predisposed to developing CCA.23,29
In conclusion, these preliminary data have highlighted the
potential importance of bile acid and PtC metabolism in patients
with CCA. These findings suggest important alterations in bio-
molecular mechanistic pathways in CCA and require further
evaluation. The putative role of bile acids as potential disease
biomarkers is novel and requires further validation in larger
studies in order to improve current diagnostic techniques aimed
at distinguishing malignant and benign biliary pathology. This
remains a major challenge for the clinician.
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